Hipertensión y Riesgo Vascular | Hipertensión y Riesgo Vascular

ISSN: 1889-1837

Hipertensión y Riesgo Vascular ha recibido Factor de Impacto (JCR) por primera vez en 2023. Guía para autores - Envío de manuscritos

Indexed in:

Web of Science, Index Medicus/MEDLINE, SCOPUS, IBECS, IME

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.2

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

1.7

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.234

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.46

View more metrics

Journal Information

Articles in press

Articles in press are accepted, peer reviewed articles that are not yet assigned to volumes/issues, but are citable using DOI. More info

HTA y depresión, una comorbilidad infravalorada

Q. Foguet-Boreu, L. Ayerbe García-Morzón

Available online 14 August 2024

Six weeks of a concurrent training therapy improves endothelial function and arterial stiffness in hypertensive adults with minimum non-responders

C. Alvarez, L. Peñailillo, P. Ibacache-Saavedra, D. Jerez-Mayorga, C. Campos-Jara, D.C. Andrade, G.V. Guimarães, E. Gomes-Ciolac, ... A.N. Gurovich

Available online 30 July 2024

Diferencia de presión arterial entre brazos: mediciones consecutivas versus simultáneas en pacientes hipertensos tratados y controlados

A. Delucchi, D. Fernández, M. Sorini, P. Reisin, M. Scarabino, P. Rodríguez

Available online 23 July 2024

View all Ahead of print

Current Issue

Issue

Vol. 41. Issue 3.

Pages 143-206 (July - September 2024)

Editorial

HT and uric acid, uric acid and HT: Is hyperuricemia a new vascular risk factor to consider?

Mencia Benitez Camps

Hipertens Riesgo Vasc. 2024;41:143-4

Originales

Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis

R.L. Sanz, F. García, A. Gutierrez, S. García Menendez, F. Inserra, L. Ferder, W. Manucha

Hipertens Riesgo Vasc. 2024;41:145-53

Assessing levels of uric acid and other cardiovascular markers in prehypertensive and hypertensive adults

L. da Cunha Agostini, L.A. Cota e Souza, N.N.T. Silva, A.C.F. Lopes, L.F. de Medeiros Teixeira, V. de Almeida Belo, W. Coura-Vital, G.N. da Silva, A.A. Lima

Hipertens Riesgo Vasc. 2024;41:154-61